Laurel Wealth Advisors (North Carolina)’s Emergent Biosolutions EBS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-50
Closed -$2K – 648
2022
Q1
$2K Hold
50
– – ﹤0.01% 577
2021
Q4
$2K Hold
50
– – ﹤0.01% 579
2021
Q3
$3K Hold
50
– – ﹤0.01% 542
2021
Q2
$3K Hold
50
– – ﹤0.01% 605
2021
Q1
$5K Hold
50
– – ﹤0.01% 495
2020
Q4
$4K Buy
+50
New +$4.59K ﹤0.01% 497

Other funds holding EBS

Laurel Wealth Advisors (North Carolina)'s EBS Position: Q2 2022 in Review

Laurel Wealth Advisors (North Carolina) sold out of Emergent Biosolutions (EBS) in Q2 2022, closing a stake of 50 shares — an estimated $2K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in EBS in Q4 2020 and held it in 6 quarters. The position peaked at $5K in Q1 2021. 231 funds tracked by Wall St. Rank hold EBS as of Q2 2022.

  • Laurel Wealth Advisors (North Carolina) reported no remaining Emergent Biosolutions position as of Q2 2022 after selling out during the quarter.
  • Laurel Wealth Advisors (North Carolina) sold 50 Emergent Biosolutions shares in Q2 2022, an estimated $2K.
  • Laurel Wealth Advisors (North Carolina) first reported a position in Emergent Biosolutions in Q4 2020 and held it in 6 quarters.
  • Laurel Wealth Advisors (North Carolina)'s Emergent Biosolutions position peaked at $5K in Q1 2021.
  • 231 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2022.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q2 2022, filed 12 Aug 2022.